PMID- 25887735
OWN - NLM
STAT- MEDLINE
DCOM- 20160115
LR  - 20240210
IS  - 1465-542X (Electronic)
IS  - 1465-5411 (Print)
IS  - 1465-5411 (Linking)
VI  - 17
DP  - 2015 Apr 9
TI  - Quantification of HER family receptors in breast cancer.
PG  - 53
LID - 10.1186/s13058-015-0561-8 [doi]
LID - 53
AB  - The clinical success of trastuzumab in breast cancer taught us that appropriate 
      tumor evaluation is mandatory for the correct identification of patients eligible 
      for targeted therapies. Although HER2 protein expression by immunohistochemistry 
      (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays 
      are routinely used to select patients to receive trastuzumab, both assays only 
      partially predict response to the drug. In the case of epidermal growth factor 
      receptor (EGFR), the link between the presence of the receptor or its 
      amplification and response to anti-EGFR therapies could not be demonstrated. Even 
      less is known for HER3 and HER4, mainly due to lack of robust and validated 
      assays detecting these proteins. It is becoming evident that, besides FISH and 
      IHC, we need better assays to quantify HER receptors and categorize the patients 
      for individualized treatments. Here, we present the current available 
      methodologies to measure HER family receptors and discuss the clinical 
      implications of target quantification.
FAU - Nuciforo, Paolo
AU  - Nuciforo P
AD  - Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Passeig Vall 
      d'Hebron 119-129, Barcelona, 08035, Spain. pnuciforo@vhio.net.
AD  - Universitat Autonoma de Barcelona, Barcelona, 08035, Spain. pnuciforo@vhio.net.
FAU - Radosevic-Robin, Nina
AU  - Radosevic-Robin N
AD  - ERTICa Research Group, University of Auvergne EA4677, 63000, Clermont-Ferrand, 
      France. nina.radosevic.robin@gmail.com.
AD  - Biopathology, Jean Perrin Comprehensive Cancer Center, 58 rue Montalembert, 
      63011, Clermont-Ferrand, France. nina.radosevic.robin@gmail.com.
FAU - Ng, Tony
AU  - Ng T
AD  - Richard Dimbleby Department of Cancer Research, Randall Division of Cell and 
      Molecular Biophysics and Division of Cancer Studies, King's College London, 
      London, SE1 1UL, UK. tony.ng@kcl.ac.uk.
AD  - UCL Cancer Institute, Paul O'Gorman Building, University College London, London, 
      WC1E 6DD, UK. tony.ng@kcl.ac.uk.
AD  - Breakthrough Breast Cancer Research Unit, Department of Research Oncology, Guy's 
      Hospital King's College London School of Medicine, London, SE1 9RT, UK. 
      tony.ng@kcl.ac.uk.
FAU - Scaltriti, Maurizio
AU  - Scaltriti M
AD  - Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, 1275 York Avenue, Box 20, New York, NY, 10065, USA. scaltrim@mskcc.org.
LA  - eng
GR  - 16463/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150409
PL  - England
TA  - Breast Cancer Res
JT  - Breast cancer research : BCR
JID - 100927353
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Breast Neoplasms/diagnosis/drug therapy/*genetics/*metabolism
MH  - ErbB Receptors/*genetics/*metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Molecular Targeted Therapy
MH  - Polymerase Chain Reaction
MH  - Protein Binding
MH  - Signal Transduction/drug effects
PMC - PMC4389676
EDAT- 2015/04/19 06:00
MHDA- 2016/01/16 06:00
PMCR- 2015/04/09
CRDT- 2015/04/19 06:00
PHST- 2015/04/19 06:00 [entrez]
PHST- 2015/04/19 06:00 [pubmed]
PHST- 2016/01/16 06:00 [medline]
PHST- 2015/04/09 00:00 [pmc-release]
AID - 10.1186/s13058-015-0561-8 [pii]
AID - 561 [pii]
AID - 10.1186/s13058-015-0561-8 [doi]
PST - epublish
SO  - Breast Cancer Res. 2015 Apr 9;17:53. doi: 10.1186/s13058-015-0561-8.